COP1 is over-expressed and acts as a negative regulator of p53 via ubiquitination in several cancers such as hepatocellular carcinoma [41], and breast and ovarian adenocarcinomas [42]; and thus COP1 is considered to be a promising target for treatment of those cancers [41]. The gene discussed is TP53; the disease is cancer.